Synthetic HDL as a new treatment for atherosclerosis regression: Has the time come?

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 4, 2008, Pages 329-335

  Conca, Paola ^a   Franceschini, Guido ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; HDL; Plaque stabilization regression; sHDL; Torcetrapib

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINOLINE DERIVATIVE; TORCETRAPIB;

ATHEROSCLEROSIS; BLOOD; DISEASE COURSE; DRUG EFFECT; HUMAN; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; HUMANS; QUINOLINES;

EID: 43949142419     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.11.001     Document Type: Short Survey

References (51)

1. The Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
3. Gordon D.J., and Rifkind B.M. High density lipoprotein: the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
4. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., and Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991) 265-267
5. Paszty C., Maeda N., Verstuyft J., and Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 94 (1994) 899-903
6. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
7. Calabresi L., Gomaraschi M., and Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23 (2003) 1724-1731
8. Kontush A., and Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58 (2006) 342-374
9. Birjmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
10. Linsel-Nitschke P., and Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4 (2005) 193-205
11. Dullens S.P., Plat J., and Mensink R.P. Increasing apoA-I production as a target for CHD risk reduction. Nutr Metab Cardiovasc Dis 17 (2007) 616-628
12. Pfizer. In interests of patient safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer News Release (December 2, 2006). http://www.businesswire.com/portal/site/pfizer/index.jsp?ndmViewId=news_view;ndmConfigId=1006532;newsId=20070226005663;newsLang=en [accessed 05.03.07]
13. Kontush A., and Chapman M.J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 3 (2006) 144-153
14. Norata G.D., Pirillo A., and Catapano A.L. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 16 (2006) 371-386
15. Favari E., Lee M., Calabresi L., Franceschini G., Zimetti F., Bernini F., et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding Cassette Transporter A1 - but not Scavenger Receptor Class B Type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 279 (2004) 9930-9936
16. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
17. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
18. Jessup W., Gelissen I.C., Gaus K., and Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 17 (2006) 247-257
19. von Eckardstein A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21 (2001) 13-27
20. Ji Y., Wang N., Ramakrishnan R., Sehayek E., Huszar D., Breslow J.L., et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 274 (1999) 33398-33402
21. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., et al. Increased high density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323 (1990) 1234-1238
22. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
23. Brousseau M.E., Diffenderfer M.R., Millar J.S., Nartsupha C., Asztalos B.F., Welty F.K., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25 (2005) 1057-1064
24. Davidson M.H., McKenney J.M., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 48 (2006) 1774-1781
25. McKenney J.M., Davidson M.H., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48 (2006) 1782-1790
26. Nissen S.E., Tardif J.C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
27. Kastelein J.J., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
28. Bots M.L., Visseren F.L., Evans G.W., Riley W.A., Revkin J.H., Tegeler C.H., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
29. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
30. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
31. Calabresi L., Gomaraschi M., Rossoni G., and Franceschini G. Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. Pharmacol Ther 111 (2006) 836-854
32. Milano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem 269 (1994) 32168-32174
33. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
34. Nanjee M.N., Doran J.E., Lerch P.G., and Miller N.E. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 19 (1999) 979-989
35. Kosek A.B., Durbin D., and Jonas A. Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem Biophys Res Commun 258 (1999) 548-551
36. Thuahnai S.T., Lund-Katz S., Williams D.L., and Phillips M.C. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem 276 (2001) 43801-43808
37. Eriksson M., Carlson L.A., Miettinen T.A., and Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 100 (1999) 594-598
38. Calabresi L., Franceschini G., Sirtori C.R., de Palma A., Saresella M., Ferrante P., et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 238 (1997) 61-65
39. Gomaraschi M., Basilico N., Sisto F., Taramelli D., Eligini S., Colli S., et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 1736 (2005) 136-143
40. Assanasen C., Mineo C., Seetharam D., Yuhanna I.S., Marcel Y.L., Connelly M.A., et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest 115 (2005) 969-977
41. Kaul S., Coin B., Hedayiti A., Yano J., Cercek B., Chyu K.Y., et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 44 (2004) 1311-1319
42. Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., and Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest 82 (1988) 803-807
43. Lerch P.G., Spycher M.O., and Doran J.E. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 80 (1998) 316-320
44. Li D., Weng S., Yang B., Zander D.S., Saldeen T., Nichols W.W., et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 19 (1999) 378-383
45. Pajkrt D., Doran J.E., Koster F., Lerch P.G., Arnet B., van der Poll T., et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184 (1996) 1601-1608
46. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
47. Bisoendial R.J., Hovingh G.K., Levels J.H., Lerch P.G., Andresen I., Hayden M.R., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003) 2944-2948
48. Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 8 (2006) 163-167
49. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 103 (2001) 3047-3050
50. Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 90 (2002) 974-980
51. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682